Reagents and antibodies will lead immuno oncology assay sales through 2036 with 37.6% of the product segment in 2026. The market was valued at USD 6.30 billion in 2025 and is expected to be worth USD 21.49 billion by 2036, creating an incremental opportunity of USD 14.44 billion.